HEPATOPROTECTIVE EFFECTOF GAMAVUTON-O AGAINST D-GALACTOSAMINE/LIPOPOL YSACCHARIDE-INDUCED FULMINANT HEPATIC FAILURE

The objective of this study is to determine the hepatoprotective effect of GVT-O(one of curcumin analogues) against liver damage in rat-induced D-galactosamine (D-GaIN)/lipopolysaccharide (LPS) as a model of fulminant hepatitis. In the study D-GaIN/LPS elevated serum GPTactivity that indicate a part...

Full description

Bibliographic Details
Main Author: Perpustakaan UGM, i-lib
Format: Article
Published: [Yogyakarta] : Universitas Gadjah Mada 2012
Subjects:
Description
Summary:The objective of this study is to determine the hepatoprotective effect of GVT-O(one of curcumin analogues) against liver damage in rat-induced D-galactosamine (D-GaIN)/lipopolysaccharide (LPS) as a model of fulminant hepatitis. In the study D-GaIN/LPS elevated serum GPTactivity that indicate a particular occurrence of liver damage due to depletion of UTP and UDP-glucuronic acid. Administration of GVT-O(10 mg/kg) showed decreased enzyme activity of SGPT/SGOTbut had no effect on serum ALP and total bilirubin levels, whereas at doses of 20 and 40 mg/kg, the protective effect of GVT-Owas decrease. The glutathione content in the D-GaIN/LPS(0.76±0.07) mol!g liver content was found lower than controls (0.90 ± 0.03) mol!g liver. Administration of GVT-O dose of 10, 20 and 40 mg/kg restored glutathione content returned to normal leVels. The results showed that treatment of GVT-O showed nO/ieffecton TBARSand catalase activity. Treatment of D- GaIN/LPS, indicating the trend of increased TNF-a, although statistically not significant, while the administration of GVT-O showed a tendency to decrease the concentration of TNF-a. All findings of the results indicated that the GVT-Omainly lower dose (10 mg/kg) showed hepatoprotective action in rat model of fulminant hepatitis induced by D-GaIN/LPS.The results indicated that the mechanism of hepatoprotective effect of GVT-Ois not via antioxidant properties of GVT-O. However, further studies are necessary to explain the molecular mechanism of hepatoprotective effect of GVT-0.